David A. Siegel Dia Medica Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.2 - $2.07 $2,160 - $3,725	-1,800 Reduced 6.74%	24,900 $31,000
Q2 2022 Aug 15, 2022	SELL	$1.86 - $2.62 $42,222 - $59,474	-22,700 Reduced 45.95%	26,700 $54,000
Q1 2022 May 16, 2022	SELL	$2.29 - $3.88 $130,988 - $221,936	-57,200 Reduced 53.66%	49,400 $124,000
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.65 $89,180 - $120,900	26,000 Added 32.26%	106,600 $398,000
Q3 2021 Nov 15, 2021	BUY	$3.1 - $4.32 $210,180 - $292,896	67,800 Added 529.69%	80,600 $323,000
Q2 2021 Aug 16, 2021	BUY	$4.45 - $9.91 $9,345 - $20,811	2,100 Added 19.63%	12,800 $57,000
Q1 2021 May 17, 2021	BUY	$7.76 - $10.43 $83,032 - $111,601	10,700 New	10,700 $98,000

3.87M

1.3K

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $116M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.